Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AUPH - Aurinia Pharmaceuticals' Lupkynis Is Approved - 120%+ Potential Upside In 5 Years

AUPH - Aurinia Pharmaceuticals' Lupkynis Is Approved - 120%+ Potential Upside In 5 Years

Aurinia Pharmaceuticals Inc
  • Lupkynis is the first FDA-approved oral therapy for lupus nephritis.
  • Approved label supports patented dosing protocol, which will last until 2037.
  • 65k annual revenue is expected per lupus nephritis patient.
  • ~10% lupus nephritis market penetration in five years will give Aurinia stock 120%+ upside.
  • A potential buyout for Aurinia is possible but will likely take some time.

For further details see:

Aurinia Pharmaceuticals' Lupkynis Is Approved - 120%+ Potential Upside In 5 Years
Stock Information
Company Name: Aurinia Pharmaceuticals Inc
Stock Symbol: AUPH
Market: NASDAQ
Website: auriniapharma.com
Menu
AUPH AUPH Quote AUPH Short AUPH News AUPH Articles AUPH Message Board
Get AUPH Alerts

News, Short Squeeze, Breakout and More Instantly...